19 Recruiting Recurrent Multiple Myeloma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by Study Phase
Top Interventions for Recurrent Multiple Myeloma
Related Conditions
Top Recruiting Recurrent Multiple Myeloma Studies
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
📍 Mary Greeley Medical Center — Ames, Iowa
View Study & Checklist ➔Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
📍 Mayo Clinic in Florida — Jacksonville, Florida
View Study & Checklist ➔Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
View Study & Checklist ➔